Welcome to our dedicated page for Envveno Medical news (Ticker: NVNO), a resource for investors and traders seeking the latest updates and insights on Envveno Medical stock.
enVVeno Medical Corporation develops bioprosthetic venous valve devices for severe deep chronic venous insufficiency in the United States. News about NVNO centers on the company’s enVVe System, a minimally invasive transcatheter replacement venous valve, and its TAVVE pivotal study under FDA investigational device exemption approval.
Recurring updates also cover the VenoValve surgical replacement venous valve, FDA communications tied to device review, clinical-development planning, cash runway and operating losses, Nasdaq listing compliance, shareholder-approved capital-structure actions such as the reverse stock split, and investor communications from this late clinical-stage medical device issuer.
enVVeno Medical Corporation (NASDAQ:NVNO) announced the successful completion of the first VenoValve surgery in its SAVVE U.S. pivotal trial, aimed at addressing severe chronic venous insufficiency (CVI) affecting 2.4 million patients in the U.S. The procedure was performed by Dr. Adriana Laser, marking a significant milestone for the company. The trial aims to enroll 75 patients across 20 centers, with expected efficacy data by the end of 2022. The VenoValve seeks to restore proper blood flow and provides a potential treatment for patients with deep vein CVI, for which there are currently no effective options.
enVVeno Medical Corporation (NASDAQ:NVNO) has successfully completed its rebranding and is now trading under the ticker symbol NVNO. Formerly known as Hancock Jaffe Laboratories, the company focuses on innovative bioprosthetic solutions for venous disease treatment. The lead product, VenoValve, aims to address deep venous Chronic Venous Insufficiency (CVI), impacting over 2.4 million people in the U.S. The device is under evaluation in the SAVVE pivotal study, with data anticipated in late 2022.